Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major

Dudley J. Pennell, John B. Porter, Maria Domenica Cappellini, Lee Lee Chan, Amal El-Beshlawy, Yesim Aydinok, Hishamshah Ibrahim, Chi Kong Li, Vip Viprakasit, Mohsen S. Elalfy, Antonis Kattamis, Gillian Smith, Dany Habr, Gabor Domokos, Bernard Roubert, Ali Taher

Research output: Contribution to journalArticlepeer-review

Abstract

Background Prospective data on cardiac iron removal are limited beyond one year and longer-term studies are, therefore, important. Design and Methods Seventy-one patients in the EPIC cardiac substudy elected to continue into the 3rd year, allowing cardiac iron removal to be analyzed over three years. Results Mean deferasirox dose during year 3 was 33.6±9.8 mg/kg per day. Myocardial T2*, assessed by cardiovascular magnetic resonance, significantly increased from 12.0 ms ±39.1% at baseline to 17.1 ms ±62.0% at end of study (P5 to

Original languageEnglish
Pages (from-to)842-848
Number of pages7
JournalHaematologica
Volume97
Issue number6
DOIs
Publication statusPublished - Jun 1 2012

Keywords

  • β-thalassemia major
  • Deferasirox
  • Iron chelation
  • Myocardial T2

ASJC Scopus subject areas

  • Hematology

Fingerprint

Dive into the research topics of 'Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major'. Together they form a unique fingerprint.

Cite this